Kastia

Rosuvastatin, the active ingredient in Kastia, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It lowers elevated cholesterol levels and is indicated for patients with hypercholesterolemia and for the prevention of cardiovascular events in at‑risk individuals.

GNH USA supplies Kastia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Kastia (rosuvastatin) acts on lipid metabolism pathways to manage cholesterol and reduce cardiovascular risk.

- Hypercholesterolemia: lowers low‑density lipoprotein (LDL) cholesterol and total cholesterol concentrations. - Primary prevention of cardiovascular disease: reduces the likelihood of first‑time heart attack or stroke in patients with elevated risk factors. - Secondary prevention of cardiovascular disease: helps prevent recurrent cardiovascular events in individuals with established heart disease.

Rosuvastatin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache: mild to moderate intensity. - Myalgia: muscle aches without weakness. - Nausea: occasional gastrointestinal discomfort. - Abdominal pain: mild stomach upset. - Elevated liver enzymes: transient increase in hepatic function tests. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with dark urine. - Hepatotoxicity: significant elevation of liver transaminases. - Acute renal failure: sudden loss of kidney function. - Severe allergic reaction: rash, swelling, or anaphylaxis. - New onset diabetes mellitus: elevated blood glucose levels. - Thrombocytopenia: reduced platelet count leading to bleeding risk.

Before initiating therapy with Kastia, consider the following safety measures.

- Pregnancy: contraindicated (Category X); avoid use during pregnancy. - Breastfeeding: not recommended; assess risk versus benefit. - Liver disease: evaluate hepatic function; use with caution. - Renal impairment: adjust dosing in severe renal dysfunction. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and direct sunlight.

Rosuvastatin may interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Cyclosporine: markedly increases rosuvastatin plasma levels. - Gemfibrozil: raises risk of myopathy and rhabdomyolysis. - Strong CYP2C9 inhibitors (e.g., fluconazole): elevate drug exposure.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin): may enhance anticoagulant effect. - Antihypertensives (e.g., amlodipine): modestly increase rosuvastatin concentrations. - Niacin: combined use can increase risk of muscle toxicity. - Digoxin: potential for increased serum digoxin levels.